Challenges remain: low-level EGFR expression in normal tissues raises on-target/off-tumor toxicity concerns; brain accumulation after intravenous dosing is constrained by the BBB; and sustained IL-15 signaling may promote NK-cell exhaustion. Here, EGFR is linked to neoplasm.